FindTrial
Sign In

Symbicort SMART

A Comparison of Symbicort SMART (160/4.5mcg) and Symbicort Turbuhaler 160/4.5mcg, Plus Terbutaline Turbuhaler 0.4mg as Needed, for Treatment of Asthma - a 12-Month, Randomized, Double-Blind, Parallel Group, Active-Controlled, Multinational Phase 3 Study in Asthmatic Patients From 16 Years

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220715
Enrollment
Unknown
Registered
2009-04-13
Start date
2009-04-13
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Interventions

investigational material(s) Generic name etc : ST INN of investigational material : Therapeutic category code : 229 Other agents affecting respiratory organs Dosage and Administration for Investigati

Sponsors

AstraZeneca
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - Diagnosis of asthma according to GINA 2007 with a documented history of at least 6 months duration - Turbuhaler-Prescribed use of inhaled GCS (any brand) for at least 12 weeksAges - Reversible airway obstruction, defined as an increase in 12% of FEV1 or more relative to baseline for all patients 15-30 minutes after inhalation of in total 2 x 0.4 mg terbutaline

Exclusion criteria

Exclusion criteria: - Respiratory infection affecting the asthma, as judged by the investigator within 4 weeks - Intake of oral, rectal or parenteral GCS within 4 weeks and/or depot parenteral GCS within 12 weeks

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026